Vyvron Review: Billed Every 4 Weeks, Not Monthly

Vyvron (vyvron.com) is a new telehealth operator selling compounded GLP-1, a microdosing program and three injectable longevity products. We checked it in August 2026. Two things about its pricing are not what the page says they are, and both change what you would actually pay.

Finding one: the month that is not a month

Vyvron's own fine print reads "$199 per 4 weeks, billed every 4 weeks; auto-renews until you cancel". Elsewhere on the same site the same plan is rendered as "$199/mo" and "starting at $199/mo".¹

Four weeks is not a month. A four-week cycle bills thirteen times in a year, not twelve. At the $199 rung, the real annual cost is $2,587 rather than the $2,388 that "$199/mo" implies — an extra $199 a year that never appears in the headline. This is a labeling error, not a hidden fee, and it is one of the more common ways a provider's advertised price and its charge history stop matching. Compare with Auren Rx, which bills on a similar cadence and says so.

Finding two: there is no monthly tirzepatide plan

Vyvron's weight-loss tiers look like three prices. They are not three prices of the same kind.

The Start tier is $199 per four weeks, billed every four weeks, and it is semaglutide only — the only genuinely recurring rung on the site. The Transform tier, badged "most popular", displays $285/mo but is charged as $790 once, for twelve weeks of tirzepatide. The Premium tier displays $248/mo and is charged as $2,981 once, for a full year.¹

So the smallest tirzepatide purchase available is $790 up front. There is no way to buy Vyvron tirzepatide for one month. Any ranking publishing "Vyvron tirzepatide, $285/mo" is publishing a price nobody can buy — which is why we file no monthly tirzepatide figure for this provider at all, rather than substituting a prepay rung, and why Vyvron does not appear on our cheapest tirzepatide ranking.

The $285 is also arithmetically odd. It divides $790 across roughly 2.77 calendar months. Divide the same $790 across three four-week cycles instead — the cadence the site actually bills on — and it is $263. Two different definitions of "per month" are in use inside one pricing table.

The founding-member framing

Vyvron advertises founding-member rates: $199 per four weeks for weight loss, $149 for microdosing and $189 for longevity, against post-founding list rates of $249, $179 and $229.¹ The homepage program cards disagree with the program pages — the homepage shows microdosing at "$179/mo", which is the post-founding list price presented as if it were the current one, and longevity at "$145/mo", which is the cheapest single longevity product rather than the program rate. We take the program pages, because that is where the enrollment button and the billing disclosure live.

The scarcity counter is not a counter. "100 of 100 founding spots left" is a hardcoded constant with a progress bar fixed at full width. It will never move.

What is actually good here

Clinical services run through OpenLoop Health, a real and substantial telehealth infrastructure company, named in the privacy policy. State disclosure is unusually specific and deserves credit: all 50 states plus DC, with a video visit required in Arkansas, DC, Delaware, Kansas, Mississippi, New Mexico, Rhode Island and West Virginia, and compounded GLP-1 unavailable in Mississippi. No other row in this batch discloses at that resolution — Auren Rx publishes no state list at all.

Longevity pricing is published per product: injectable NAD+ at $229 a month, injectable sermorelin at $229, injectable B12-MIC at $145.

What is missing

No pharmacy is named. No prescriber is named, and no NPI is published, so nothing can be checked against the national registry — the verification step described in how to tell if a GLP-1 provider is legit.

You are charged when you complete the intake, before a provider reviews it. A full refund is available only if you cancel within 72 hours with no services rendered, or if a provider medically disqualifies you. Cancellation requires 72 hours' notice before the next billing date or you are charged for that cycle. Prepaid Transform and Premium plans refund only the months whose medication has not shipped — which is a meaningful risk on a $2,981 annual prepay.

Vyvron's testimonial section ships placeholders stating that patient stories will appear once written consent is obtained from founding members. That is honest, and it is also an unambiguous statement that this company has no track record yet.

The regulatory screen

The trading name and its clinical partner both returned zero company-column matches in the FDA's live warning-letter index in August 2026, in a pass whose positive control correctly returned a known 2026 letter for an unrelated seller.² Clean, but a clean regulatory record on a company with no operating history is a weaker signal than the same record on an established one.

Where it lands

If you want semaglutide, Vyvron's $199 per four weeks is a fair rung, provided you budget thirteen of them a year. If you want tirzepatide, there is no monthly option and the entry ticket is $790. If you want a provider with a track record, this is not one yet. Read it against The Edit, Trellis Vitality and the rest of our evidence library.